Search results
Showing 1 to 15 of 152 results for ischemic heart disease
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)
In development Reference number: GID-HTE10085 Expected publication date: 02 December 2026
Topic prioritisation
Rheumatoid arthritis: cardiovascular risk assessment (IND108)
This indicator covers the percentage of patients with rheumatoid arthritis (RA) aged 30 to 84 years who have had a cardiovascular risk assessment using a cardiovascular disease (CVD) risk assessment tool adjusted for RA in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM56
Angina and coronary heart disease: anti-platelet or anticoagulation (IND132)
This indicator covers the percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM88.
This indicator covers the contractor establishing and maintaining a register of patients with coronary heart disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM235
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Bioresorbable stent implantation to treat coronary artery disease (HTG633)
Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.
View recommendations for HTG633Show all sections
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)
Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.
View recommendations for HTG747Show all sections
This indicator covers the percentage of patients with coronary heart disease (CHD) who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM87
Familial hypercholesterolaemia: identification and management (CG71)
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.